Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527423 · ClinicalTrials.gov registry record · Phase 2
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
NCT00527423: Completed Phase 2 study, sponsored by Regeneron Pharmaceuticals.
NCT00527423 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 157 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00527423, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
Study Summary
Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular degeneration.
Primary Outcome
Number of participants with AEs summarized by category
Interventions
- DRUG VEGF Trap Eye
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT00527423 record still lists
NCT00527423 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% higher).
The record links to 0 conditions, and to 1 intervention - of which VEGF Trap Eye is the first listed.
NCT00527423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00527423 about?
NCT00527423 is a clinical study titled "Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD". Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular degeneration.
What is the current status of trial NCT00527423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2007-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00527423?
The interventions under investigation include: VEGF Trap Eye (DRUG).
Who is sponsoring clinical trial NCT00527423?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00527423's enrollment target sits among peer trials
157 443rd of 2000 higher than 1,556 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia